Editorial: Treatment of patients with HCV-related cirrhosis with peginterferon and ribavirin: Swinging the pendulum toward treatment

American Journal of Gastroenterology

Volumn 105, Issue 10, 2010, Pages 2174-2176

  Noureddin, Mazen ^a   Ghany, Marc G ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SERUM ALBUMIN; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ASCITES; COMPARATIVE STUDY; CYTOPENIA; DECOMPENSATED LIVER CIRRHOSIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ESOPHAGUS VARICES; HEPATIC ENCEPHALOPATHY; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; COMPLICATION; HEPACIVIRUS; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 77957828106     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.288     Document Type: Review

References (20)

1. Williams R. Global challenges in liver disease. Hepatology 2006; 44: 521-6. (Pubitemid 44433707)
2. Serfaty L, Aumaitre H, Chazouilleres O et al. Determinants of outcome ofcompensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435-40. (Pubitemid 28227875)
3. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensatedcirrhosis type C: a retrospective follow-up study of 384 patients.Gastroenterology 1997; 112: 463-72. (Pubitemid 27078833)
4. Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C:results of a large, prospective cohort study. Hepatology 1998; 28: 1687-95. (Pubitemid 28549142)
5. Benvegnu L, Gios M, Boccato S et al. Natural history of compensated viralcirrhosis: a prospective study on the incidence and hierarchy of majorcomplications. Gut 2004; 53: 744-9. (Pubitemid 38561455)
6. Hu KQ, Tong MJ. The long-term outcomes of patients with compensatedhepatitis C virus-related cirrhosis and history of parenteral exposure in theUnited States. Hepatology 1999; 29: 1311-6.
7. Mallet V, Gilgenkrantz H, Serpaggi J et al. Brief communication: the relationshipof regression of cirrhosis to outcome in chronic hepatitis C. AnnIntern Med 2008; 149: 399-403.
8. Bruno S, Stroffolini T, Colombo M et al. Sustained virological response tointerferon-alpha is associated with improved outcome in HCV-relatedcirrhosis: a retrospective study. Hepatology 2007; 45: 579-87. (Pubitemid 46453759)
9. Hung CH, Lee CM, Lu SN et al. Long-term effect of interferon alpha-2bplus ribavirin therapy on incidence of hepatocellular carcinoma in patientswith hepatitis C virus-related cirrhosis. J Viral Hepat 2006; 13: 409-14.
10. Veldt BJ, Heathcote EJ, Wedemeyer H et al. Sustained virologic responseand clinical outcomes in patients with chronic hepatitis C and advancedfibrosis. Ann Intern Med 2007; 147: 677-84. (Pubitemid 351664462)
11. Fernández-Rodríguez CM, Alonso S, Martinez SM et al. Peginterferonplus ribavirin and sustained virological response in HCV-relatedcirrhosis: outcomes and factors predicting response. Am J Gastroenterol2010;105:2164-72 (this issue).
12. Syed CM, Rahbin N, Martinez SM et al. Pegylated interferon and ribavirincombination therapy for chronic hepatitis C virus infection in patients withChild-Pugh Class A liver cirrhosis. Scand J Gastroenterol 2008; 43: 1378-86.
13. Di Marco V, Almasio PL, Ferraro D et al. Peg-interferon alone or combinedwith ribavirin in HCV cirrhosis with portal hypertension: a randomizedcontrolled trial. J Hepatol 2007; 47: 484-91. (Pubitemid 47336987)
14. Helbling B, Jochum W, Stamenic I et al. HCV-related advanced fibrosis/cirrhosis:randomized controlled trial of pegylated interferon alpha-2a andribavirin. J Viral Hepat 2006; 13: 762-9. (Pubitemid 44583502)
15. Abergel A, Hezode C, Leroy V et al. Peginterferon alpha-2b plus ribavirinfor treatment of chronic hepatitis C with severe fibrosis: a multicentrerandomized controlled trial comparing two doses of peginterferon alpha-2b.J Viral Hepat 2006; 13: 811-20.
16. Marrache F, Consigny Y, Ripault MP et al. Safety and efficacy of peginterferonplus ribavirin in patients with chronic hepatitis C and bridgingfibrosis or cirrhosis. J Viral Hepat 2005; 12: 421-8. (Pubitemid 40961483)
17. Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon alfa-2a in patientswith chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80.
18. Shiffman ML, Ghany MG, Morgan TR et al. Impact of reducing peginterferonalfa-2a and ribavirin dose during retreatment in patients with chronichepatitis C. Gastroenterology 2007; 132: 103-12.
19. Bruno S, Shiffman ML, Roberts SK et al. Efficacy and safety of peginterferonalfa-2a (40KD) plus ribavirin in hepatitis C patients with advancedfibrosis and cirrhosis. Hepatology 2010; 51: 388-97.
20. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a andribavirin combination therapy in chronic hepatitis C: a randomized study oftreatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.